Bystin inhibitors represent a class of chemical compounds that have garnered attention in the field of molecular biology and cellular processes research. These inhibitors are specifically designed to target and modulate the activity of Bystin, which is also known as DPAGT1 (Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1). Bystin is a critical enzyme involved in the N-linked glycosylation pathway, a fundamental cellular process that modifies proteins by attaching sugar molecules to them within the endoplasmic reticulum (ER). N-linked glycosylation plays a pivotal role in protein folding, stability, and trafficking, ensuring the proper functioning of numerous secretory and membrane proteins.
Bystin inhibitors exert their effects by interfering with the enzymatic activity of Bystin, disrupting its role in the N-linked glycosylation pathway. This interference can lead to the misfolding or improper glycosylation of proteins, affecting their stability and trafficking within the cell. Researchers employ Bystin inhibitors as valuable tools to investigate the specific roles of Bystin in different cellular contexts and to gain insights into the molecular mechanisms governing protein glycosylation and its implications for cellular physiology. While the precise applications and broader implications of Bystin inhibitors are subjects of ongoing research, their utility in elucidating the intricacies of protein modification and quality control within the ER is of paramount importance in advancing our understanding of cell biology and its relevance to various cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Affects gene transcription and may downregulate Bystin expression as it influences cell differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can alter cell growth and proliferation pathways, possibly affecting Bystin expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Alters autophagy and endosomal/lysosomal pathways, which could indirectly modulate the expression of Bystin. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Inhibits protein synthesis leading to reduced expression of many proteins, potentially including Bystin. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase, potentially reducing Bystin transcription. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Blocks N-linked glycosylation, which can affect the stability and expression of glycoproteins, possibly altering Bystin levels. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that may disrupt multiple signaling pathways, possibly decreasing Bystin expression. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Disrupts hypoxia-inducible factor (HIF) pathways, which could affect the expression of various genes, including Bystin. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
An Hsp90 inhibitor which can affect the stability of multiple client proteins, potentially impacting Bystin expression. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $115.00 $337.00 | 3 | |
Can trigger pathways leading to apoptosis, which might reduce Bystin expression as a secondary effect. |